Articles tagged "Hepatocellular carcinoma"

2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
K. Nunez, T. Sandow, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
2020 American Transplant Congress
Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy
A. Mathur, E. Baughan, A. Griesemer, M. Najjar, O. Perez, A. Qian, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…
2020 American Transplant Congress
The Perioperative Coagulation Profile of Hepatocellular Carcinoma During Liver Transplantation Compared to Patients with Non-Malignant Disease: A Cause or Association for Decreased Blood Product Utilization During Liver Transplantation?
H. B. Moore, E. Pomfret, J. Pomposelli, C. Walker, R. Choudhury, H. Yaffe, M. Wachs, T. Bak, K. Conzen, M. Adams, T. Pshak, T. L. Nydam
University of Colorado, Aurora, CO
*Purpose: Hepatobiliary malignancies have been associated with hyper-coagulability. However, the impact of hepatocellular carcinoma (HCC) on coagulation during liver transplantation remains less clear. We hypothesize…
2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
T. Kitajima¹, S. Nagai¹, D. Moonka², S. Yeddula¹, O. Rizzo¹, M. Kavousi¹, R. Salgia², M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…
2020 American Transplant Congress
Waiting List Mortality of Liver Tumors
V. G. Menon, Y. Chen, D. C. Chang, H. Yeh
Division of Transplantation, Massachusetts General Hospital, Boston, MA
*Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics
C. Durkin¹, D. E. Kaplan², T. Bittermann²
¹Internal Medicine, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology, University of Pennsylvania, Philadelphia, PA
*Purpose: A United Network for Organ Sharing (UNOS) policy change in 2015 created a 6-month delay in the receipt of T2 hepatocellular carcinoma (HCC) exception…
2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
M. L. Goldman¹, K. Zhou², J. L. Dodge¹, F. Yao¹, N. Mehta¹
¹Department of Medicine, UCSF, San Francisco, CA, ²Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
2020 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria
A. Thorat, L. Jeng, S. Hsu, H. Yang, P. Li, T. Chen, K. Poon
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…
2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
P. Tabrizian¹, M. Holzner², V. Agopian³, R. Busuttil³, G. Sapisochin⁴, N. Mehta⁵, F. Yao⁵, J. Roberts⁶, S. Florman¹, M. E. Schwartz¹, T. Ivanics⁷, J. Emond⁸, B. Samstein⁹, R. Brown, MD, MPH⁹, M. Najjar¹⁰, W. Chapman¹¹, M. Doyle¹¹, K. Halazun⁹
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Surgery, Georgetown University Hospital, Washington DC, MD, ³Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Transplant, Univeristy of Toronto, Toronto, ON, Canada, ⁵Transplant, UCSF, San Francisco, CA, ⁶Transplantation, UCSF, San Francisco, CA, ⁷Transplant, University of Toronto, Toronto, ON, Canada, ⁸Transplant, Columbia University Medical Center, New York, NY, ⁹Transplant, Weill Cornell Medical Center, New York, NY, ¹⁰Transplant, Columbia Medical Center, New York, NY, ¹¹Transplant, Washington University School of Medicine, St Louis, MO
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…